Adverse drug reactions to dopamine agonists: A comparative study in the French pharmacovigilance database

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1876-1880

  Perez Lloret, Santiago ^a   Bondon Guitton, Emmanuelle ^a   Rascol, Olivier ^a   Montastruc, Jean Louis ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse drug reactions; Apomorphine; Bromocriptine; Dopamine agonists; Pergolide; Pharmacovigilance; Pramipexole; Ropinirole

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; QUINAGOLIDE; ROPINIROLE;

ARTICLE; CARDIOTOXICITY; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; DATA BASE; DISORIENTATION; DRUG SURVEILLANCE PROGRAM; EDEMA; EYE TOXICITY; FRANCE; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; HYPOTENSION; IMPULSE CONTROL DISORDER; METABOLIC DISORDER; NAUSEA; NEUROTOXICITY; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; SOMNOLENCE; VALVULAR HEART DISEASE; VOMITING; FACTUAL DATABASE; RISK;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DOPAMINE AGONISTS; FRANCE; HUMANS; LEVODOPA; ODDS RATIO;

EID: 77956792132     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23204     Document Type: Article

References (24)

1. Sweetman SC. Martindale: the complete drug reference. Medicines complete (online). Available from URL:http://www. medicinescomplete.com/mc/martindale/ current/ (Accessed June 1, 2009).
2. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-1078. (Pubitemid 44374749)
3. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-393.
4. Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008;9:715-726.
5. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008;16:CD006564.
6. Steiger M, Jost W, Grandas F, Van CG. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 2009;116:179-191.
7. Spreux A, Baldin B, Chichmanian RM. Pharmacovigilance in practice. Transfus Clin Biol 1999;6:254-259.
8. Montastruc JL, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine 2006;73:629-632. (Pubitemid 44932244)
9. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-1259.
10. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007;30:891-898. (Pubitemid 47481444)
11. Ravoire S, for Lilly France. Information Importante de Pharmacovigilance CELANCE. Agence Francaise de Sécurité Sanitaire des Produits de Santé (online). Available from URL:http://www. afssaps.fr/Infos-de- securite/Lettres-aux-professionnels-de-sante/Celance- R-pergolide/ %28language%29/fre-FR (Accessed Oct 28, 2009).
12. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910. (Pubitemid 29260911)
13. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428. (Pubitemid 30248740)
14. Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288:1588.
15. Pierfitte C, Begaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999;47:329-331.
16. Tavassoli N, Lapeyre-Mestre M, Sommet A, Montastruc JL. Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol). Br J Clin Pharmacol 2009;68:422-426.
17. Montastruc G, Favreliere S, Sommet A, et al. Drugs and dilated cardiomyopathies: a case/non-case study in the French pharmacovigilance database. Br J Clin Pharmacol 2010;69:287-294.
18. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004;61:97-102.
19. Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005;62:1242-1248. (Pubitemid 41168351)
20. Micallef J, Rey M, Eusebio A, et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009;67:333-340.
21. Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62:S32-S36.
22. Fabre N, Montastruc JL, Rascol O. Alopecia: an adverse effect of bromocriptine. Clin Neuropharmacol 1993;16:266-268.
23. Burchill SA, Thody AJ, Ito S. Melanocyte-stimulating hormone, tyrosinase activity and the regulation of eumelanogenesis and phaeomelanogenesis in the hair follicular melanocytes of the mouse. J Endocrinol 1986;109:15-21. (Pubitemid 16111839)
24. Sharif NA, McLaughlin MA, Kelly CR, et al. Cabergoline: pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res 2009;88:386-397.